News

Progression of ALS linked to a membrane and an enzyme

Matthew Coslett
By Matthew Coslett
Feb. 17, 2024

Researchers at Nagoya University in Japan have discovered a relationship between the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and the disruption of mitochondria-associated membranes (MAM), the contact point between the mitochondria and the endoplasmic reticulum (ER) of the cell. This discovery, published in the Proceedings of the National Academy of Sciences, provides important information about the mechanisms behind this neurodegenerative condition. 

ALS is a complex disease that affects motor neurons. Previous studies have found that mitochondria, the energy-generating cells of the body, and the ER, a complex membrane network that serves protein synthesis, metabolism, and calcium storage, are involved. The MAM is where the ER interfaces with mitochondria. Although both mitochondria and ER abnormality, especially at the MAM, play a role in the progression of the disease, it is not clear how. 

Diminished activities of the enzyme TBK1 in mitochondrial-associated membrane reduces motor neurons’ tolerance to stressors, a causative factor in the disease.
Reiko Matsushita
Diminished activities of the enzyme TBK1 in mitochondrial-associated membrane reduces motor neurons’ tolerance to stressors, a causative factor in the disease.

One possible agent is TANK-binding kinase 1 (TBK1), an enzyme that plays a crucial role in various biological processes, including inflammation and clearing damaged proteins from cells. Its disruption is important in the development of many diseases. Although mutations in the TBK1 gene cause ALS, it is not clear how TBK1 malfunctions lead to its development.  

A team led by Koji Yamanaka at Nagoya University’s Research Institute of Environmental Medicine, in collaboration with Masahisa Katsuno of the Graduate School of Medicine discovered that brain and spinal cord tissues in ALS patients as well as mice with a disrupted MAM showed decreased activation of TBK1. 

Seiji Watanabe, the first author of the study, explained: "TBK1 is crucial for stress response in motor neurons. If we reduce its activity, it will result in reduced tolerance to stressors, leading to neurotoxicity and eventual motor neuron death. This finding is particularly significant because abnormal protein accumulation and the resulting stress cause ALS and other neurodegenerative diseases." 

When MAM is disrupted in ALS, TBK1 activity decreases. When the researchers administered arsenite, an agent that lowers TBK1 activity and disrupts MAM, to mice, they found that the mice exhibited motor problems similar to ALS. 

Yamanaka added, "Our study strongly suggests that MAM significantly influences the stress response of motor neurons through TBK1 activation. Our study is consistent with human genetic studies that reported that TBK1 mutations cause ALS. Restoring TBK1 activity emerges as a potential therapeutic strategy to counter ALS, marking a promising direction for future research endeavors." 

By focusing on the TBK1 pathway, the researchers have found a critical foundation for developing new ways to treat ALS and possibly other brain disorders. “We expect these results to lead to the development of new therapeutic strategies for ALS in the future,” said Yamanaka. “In future projects, restoring the TBK1 activity (or function) may be a therapeutic strategy to treat ALS.” 

This article was originally published on the Nagoya University NU Research Information page. Read the original here.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Matthew Coslett
Matthew Coslett

Matthew Coslett is a science communicator and lead science writer at Nagoya University in Japan. He holds a master of sciences degree in science communication with research interests in how organizations communicate science online and cross-cultural communication. He is a strong believer that science is for everyone and anyone can understand it with the right approach.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

From the Journals: JBC
Journal News

From the Journals: JBC

March 25, 2025

How cells recover from stress. Cancer cells need cysteine to proliferate. Method to make small membrane proteins. Read about papers on these topics recently published in the Journal of Biological Chemistry.

ASBMB names 2025 JBC/Tabor Award winners
Award

ASBMB names 2025 JBC/Tabor Award winners

March 24, 2025

The six awardees are first authors of outstanding papers published in 2024 in the Journal of Biological Chemistry.

Pan-kinase inhibitor for head and neck cancer enters clinical trials
Journal News

Pan-kinase inhibitor for head and neck cancer enters clinical trials

March 18, 2025

A drug targeting the scaffolding function of multiple related kinases halts tumor progression.